• 1
    Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 17331745.
  • 2
    Hoofnagle JH, di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997; 336: 347356.
  • 3
    Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000; 119: 172180.
  • 4
    Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808816.
  • 5
    Aloman C, Wands JR. Resistance of HBV to adefovir dipivoxil: a case for combination antiviral therapy? HEPATOLOGY 2003; 38: 15841587.
  • 6
    Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125: 292297.
  • 7
    Chisari FV. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995; 13: 2960.
  • 8
    Ferrari C, Penna A, Bertoletti A, Valli A, Antoni AD, Giuberti T, et al. Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. J Immunol 1990; 145: 34423449.
  • 9
    Penna A, Del Prete G, Cavalli A, Bertoletti A, D'Elios MM, Sorrentino R, et al. Predominant T-helper 1 cytokine profile of hepatitis B virus nucleocapsid-specific T cells in acute self-limited hepatitis B. HEPATOLOGY 1997; 25: 10221027.
  • 10
    Bertoletti A, D'Elios MM, Boni C, De Carli M, Zignego AL, Durazzo M, et al. Different cytokine profiles of intraphepatic T cells in chronic hepatitis B and hepatitis C virus infections. Gastroenterology 1997; 112: 193199.
  • 11
    Jung MC, Hartmann B, Gerlach JT, Diepolder H, Gruber R, Schraut W, et al. Virus-specific lymphokine production differs quantitatively but not qualitatively in acute and chronic hepatitis B infection. Virology 1999; 261: 165172.
  • 12
    Rehermann B, Lau D, Hoofnagle JH, Chisari FV. Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J Clin Invest 1996; 97: 16551665.
  • 13
    Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, Urbani S, et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998; 102: 968975.
  • 14
    Boni C, Penna A, Ogg GS, Bertoletti A, Pilli M, Cavallo C, et al. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. HEPATOLOGY 2001; 33: 963971.
  • 15
    Livingston BD, Crimi C, Grey H, Ishioka G, Chisari FV, Fikes J, et al. The hepatitis B virus-specific CTL responses induced in humans by lipopeptide vaccination are comparable to those elicited by acute viral infection. J Immunol 1997; 159: 13831392.
  • 16
    Heathcote J, McHutchison J, Lee S, Tong M, Benner K, Minuk G, et al. A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group. HEPATOLOGY 1999; 30: 531536.
  • 17
    Couillin I, Pol S, Mancini M, Driss F, Brechot C, Tiollais P, et al. Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens. J Infect Dis 1999; 180: 1526.
  • 18
    Pol S, Nalpas B, Driss F, Michel ML, Tiollais P, Denis J, et al. Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. J Hepatol 2001; 34: 917921.
  • 19
    Donnelly JJ, Ulmer JB, Shiver JW, Liu MA. DNA vaccines. Annu Rev Immunol 1997; 15: 617648.
  • 20
    Mancini M, Hadchouel M, Davis HL, Whalen RG, Tiollais P, Michel ML. DNA-mediated immunization in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state. Proc Natl Acad Sci U S A 1996; 93: 1249612501.
  • 21
    Rollier C, Sunyach C, Barraud L, Madani N, Jamard C, Trepo C, et al. Protective and therapeutic effect of DNA-based immunization against hepadnavirus large envelope protein. Gastroenterology 1999; 116: 658665.
  • 22
    Pancholi P, Lee DH, Liu Q, Tackney C, Taylor P, Perkus M, et al. DNA prime/canarypox boost-based immunotherapy of chronic hepatitis B virus infection in a chimpanzee. HEPATOLOGY 2001; 33: 448454.
  • 23
    Tacket CO, Roy MJ, Widera G, Swain WF, Broome S, Edelman R. Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device. Vaccine 1999; 17: 28262829.
  • 24
    Roy MJ, Wu MS, Barr LJ, Fuller JT, Tussey LG, Speller S, et al. Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 2000; 19: 764778.
  • 25
    MacGregor RR, Boyer JD, Ugen KE, Lacy KE, Gluckman SJ, Bagarazzi ML, et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: Safety and host response. J Infect Dis 1998; 178: 92100.
  • 26
    Michel M-L, Davis HL, Schleef M, Mancini M, Tiollais P, Whalen RG. DNA-mediated immunization to the hepatitis B surface antigen in mice: Aspects of the humoral response mimic hepatitis B viral infection in humans. Proc Natl Acad Sci U S A 1995; 92: 53075311.
  • 27
    Mancini M, Davis HL, Tiollais P, Michel M-L. DNA-based immunization against the envelope proteins of the hepatitis B virus. J Biotechnol 1996; 44: 4757.
  • 28
    Davis HL, McCluskie MJ, Gerin JL, Purcell RH. DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines. Proc Natl Acad Sci U S A 1996; 93: 72137218.
  • 29
    Loirat D, Lemonnier FA, Michel ML. Multiepitopic HLA-A*0201-restricted immune response against hepatitis B surface antigen after DNA-based immunization. J Immunol 2000; 165: 47484755.
  • 30
    Michel ML, Pontisso P, Sobczak E, Malpiece Y, Streeck RE, Tiollais P. Synthesis in animal cells of hepatitis B surface antigen particles carrying a receptor for polymerized human serum albumin. Proc Natl Acad Sci U S A 1984; 81: 77087712.
  • 31
    Ferrari C, Bertoletti A, Penna A, Cavalli A, Valli A, Missale G, et al. Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen. J Clin Invest 1991; 88: 214222.
  • 32
    Larsson M, Jin X, Ramratnam B, Ogg GS, Engelmayer J, Demoitie MA, et al. A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals. AIDS 1999; 13: 767777.
  • 33
    Bertoletti A, Naoumov NV. Translation of immunological knowledge into better treatments of chronic hepatitis B. J Hepatol 2003; 39: 115124.
  • 34
    Pol S, Driss F, Carnot F, Michel ML, Berthelot P, Brechot C. Efficacy of immunotherapy with vaccination against hepatitis B virus on virus B multiplication. C R Acad Sci III 1993; 316: 688691.
  • 35
    Ren F, Hino K, Yamaguchi Y, Funatsuki K, Hayashi A, Ishiko H, et al. Cytokine-dependent anti-viral role of CD4-positive T cells in therapeutic vaccination against chronic hepatitis B viral infection. J Med Virol 2003; 71: 376384.
  • 36
    Akbar SM, Kajino K, Tanimoto K, Kurose K, Masumoto T, Michitaka K, et al. Placebo-controlled trial of vaccination with hepatitis B virus surface antigen in hepatitis B virus transgenic mice. J Hepatol 1997; 26: 131137.
  • 37
    Reignat S, Webster GJ, Brown D, Ogg GS, King A, Seneviratne SL, et al. Escaping high viral load exhaustion: CD8 cells with altered tetramer binding in chronic hepatitis B virus infection. J Exp Med 2002; 195: 10891101.
  • 38
    Webster GJ, Reignat S, Brown D, Ogg GS, Jones L, Seneviratne SL, et al. Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol 2004; 78: 57075719.
  • 39
    Webster GJ, Reignat S, Maini MK, Whalley SA, Ogg GS, King A, et al. Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. HEPATOLOGY 2000; 32: 11171124.
  • 40
    Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401: 708712.
  • 41
    Boni C, Penna A, Bertoletti A, Lamonaca V, Rapti I, Missale G, et al. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol 2003; 39: 595605.
  • 42
    Urbani S, Boni C, Missale G, Elia G, Cavallo C, Massari M, et al. Virus-specific CD8+ lymphocytes share the same effector-memory phenotype but exhibit functional differences in acute hepatitis B and C. J Virol 2002; 76: 1242312434.
  • 43
    Cooksley H, Chokshi S, Wedemeyer H, Andreone P, Gilson R, Warnes T, et al. Hepatitis B virus-specific T-cell reactivity during Adefovir Dipivoxil (ADV) treatment: a multicentre, controlled study. J Hepatol 2002; 36 ( Suppl 1): 7.
  • 44
    Berzofsky JA, Ahlers JD, Belyakov IM. Strategies for designing and optimizing new generation vaccines. Nat Rev Immunol 2001; 1: 209219.